ATR and neoplasm: Tumor hypoxia is a unique feature of most solid tumors including treatment‐resistant TNBCs and remains a barrier to their successful treatment.[42, 58] Thus, in this study, we demonstrate the potential of hypoxia‐specific delivery of AZD6738 to selectively eradicate hypoxic cancer cells, whilst minimising the normal cell toxicities associated with ATR inhibition.